RETRACTION: Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer
To our readers: With deep regrets, we inform our Readers that the article Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer (DOI: http://dx.doi.org/10.4081/oncol.2014.236), which has been published Ahead of Print in the first issue of Oncology...
Saved in:
Main Author: | Camillo Porta (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2014-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RETRACTED - Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer
by: Yousif Abubakr, et al.
Published: (2014) -
Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis
by: Zhen-Yu Li, et al.
Published: (2023) -
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
by: Paplomata E, et al.
Published: (2013) -
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
by: Koji Takada, et al.
Published: (2021) -
Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
by: Duan F, et al.
Published: (2021)